The domestic Covid oral drug Azvudine is priced below 300 yuan, and the annual output is expected to reach 3 billion tablets
2022-08-08: [Article Link]
The price of the first national drug, Covid-19 oral "Azvudine" (Azvudine), was set at a price not greater than 300 Yuan (the same as RMB), 35 units per bottle, 1 mg per pill.
On 2 August, Azov from Henan Real Biotech Ltd. (hereinafter referred to as Real Life) was put into production on the flattops, producing up to 3 billion tablets a year in the future.
Last July, Azov was ordered to be marketed as a cure for HIV/AIDS, which was commissioned by the Real Life Commission, Beijing and Pharmaceutical Plants Ltd. In May, the Real Biotops Production Base went through the Henan Provincial Drug Surveillance Authority’s regulatory compliance for the quality control of pharmaceutical products, marking the company’s own production base for the production and operation of pharmaceutical products. The Azov film has been put on the market.
On 25 July, the National Drug Control Service, in accordance with the provisions of the Medicines Management Act, conducted an urgent review and review process in accordance with the special examination procedure for pharmaceutical products, with the proviso that the real organism Azov would increase the application to register for treatment of the covid-19 virus pneumonia.
The price of Azov's tablets is better than the price of the US pharmaceutical factory Pfizer's covid-19 oral drug, Paxlovid, and China's first autonomous anti-Covid-19 virus and the anti-college drug, the Ambaway Unit and the Romisway Unit Injection fluid. Covid-19: On November 16, 2021, Pixlovid was being produced and packaged by the Pixel Pharmacy Plant.
According to public data, the price of Paxlovid is 2300Yuan per course of treatment, and the legal price of the combined treatment with the antibodies is less than 10000Yuan per person.
The Azov film has been put on the market, except for in-house experts who have revealed that it will take at least three to six months for a drug to be placed on the market after an application has been accepted.
Each new drug needs to be registered in a health facility, and the test data will be collected and collated into a registered file, including validity and safety data, to demonstrate the ultimate use of the drug.
On August 2nd, Henan Real BioTech Covid-19 oral Azov dictation ceremony (WeChat Public @Real BioTech) was organized by Henan Real BioTech Ltd.
According to the announcement of the Medical Discovery, the company and real life will be linked to the development and exclusive commercialization of the Azov film by a controlled company, Medical Medicines for Stars, in collaboration with the Covid-19 virus, AIDS treatment and preventive fields. On the evening of 4 August, real life handed over to Hong Kong its first application for a public fund-raising fund (IPO), in which it was stated that the fund-raising fund was used primarily to finance the purchase of medical supplies needed to produce chemicals in the Azov commercial industry, as well as to finance the expansion of the production capacity of production plants on the mountaintops.
"Azvte" has 35 bottles of 1 mg each, each at a price less than 300 Yuan.
In April of this year, real-life II stop-bed research was developed, and after covid-19 patients received oral Azov, the results of the nucleic acid test were turned negative from 3 to 4 days, with an average of 6 to 7 days of medication and an average of 9 days of discharge from hospital, with severe and mild treatments having the same effect. On July 15, Real Organisms published the results of the Triple III impregnation test. The results show that Azov was first ordered to improve the incidence of bed impregnation in the seventh day of the drug by 40.43 per cent, the placebo group by 10.87 per cent, and that the Azov group and the placebo group at the midpoint of the subject's bed impregnated symptoms were significantly different from the statistical differences (P <0.001).